Navigation Links
Heska Announces Q4 and Annual 2007 Results
Date:2/26/2008

d by the prospects for our diagnostic instruments, where we launched three major new products in 2007."

Total Revenue

Total revenue for the fourth quarter of 2007 was $20.0 million, a decrease of 2% compared to the fourth quarter of 2006. 2007 total revenue was $82.3 million, up 10% compared to $75.1 million in 2006. Total revenue consists of product revenue and research, development and other revenue, both of which are discussed below.

Segment Product Revenue

Total product revenue for the fourth quarter of 2007 was $19.7 million, up 7% from $18.5 million in the fourth quarter of 2006. For the year ended December 31, 2007, total product revenue was $80.8 million, up 13% from $71.8 million in 2006. Heska Corporation's business is comprised of two reportable segments -- Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. Product revenue from these segments is as follows:

Core Companion Animal Health This segment includes revenue from the Company's diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals, primarily for canine and feline use. In the fourth quarter of 2007, this segment generated product revenue of $17.1 million, up 11% as compared to $15.4 million in the fourth quarter of 2006. For the year ended December 31, 2007, this segment generated product revenue of $65.9 million, up 10% from $59.9 million in 2006.

Other Vaccines, Pharmaceuticals and Products This segment includes revenue from private label vaccine and pharmaceutical production, primarily for cattle but also for other animals including small mammals and fish. In the fourth quarter of 2007, this segment generated product revenue of $2.6 million, down 15% as compared to $3.1 million in the fourth quarter of 2006. In 2007, this segment generated product revenue of $14.9 million up 25% from $11.9 million in 2006. Results for the year ended December 31, 2007 include approximately $1
'/>"/>

SOURCE Heska Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Heska Announces Third Quarter 2007 Earnings Conference Call Webcast
2. Heska to Present at Friedland Investment Events Life Sciences Conference
3. Heska to Present at the BioWest 2007 Mature Company Forum
4. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
5. Heska Announces Amended Agreement With AgriLabs
6. Louise McCormick Joins Heskas Board of Directors
7. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2007 Earnings Conference Call Webcast
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... 26, 2014 (HealthDay News) -- Most babies and young ... the U.S. Food and Drug Administration says. Over-the-counter ... to children younger than 2 because they could cause ... American adults average about three colds a year, ... a cold, parents might want to give them pain ...
(Date:11/27/2014)... 27, 2014 In order to enable people ... Fla., designed an easy way to avoid touching a toilet ... then created a prototype of the patent-pending Toilet Tamer, a ... toilet seat and/or lid in a more sanitary manner. It ... of germs. Overall, it promotes good hygiene and peace of ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
(Date:11/27/2014)... VogueQueen.com is making every effort to ... the world. As the premier online supplier of elegant ... to release a huge selection of sexy prom dresses ... is also providing many beautiful styles in its product ... at discounted prices. , “VogueQueen.com hopes to provide a ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2
... mid-October, ahead of vaccine delivery , THURSDAY, Sept. 10 (HealthDay ... flu outbreak is expected in October, but a planned vaccine ... suggests. , The first batch of the new H1N1 vaccine, ... according to the U.S. Centers for Disease Control and Prevention. ...
... Boston Scientific Corporation (NYSE: BSX ) is scheduled to ... , Ray Elliott, President and Chief Executive Officer ... participate in a 35-minute discussion about the Company on Tuesday, September ... , A live webcast of this discussion will be ...
... ... reconstruction, quicker recovery and more natural knee motion post-surgery , ... Evanston, Illinois (Vocus) -- NorthShore University ... use a new and innovative robotic technology for minimally-invasive partial knee replacement ...
... , , WOODCLIFF ... today announced that it has received final approval from the U.S. ... nateglinide tablets. Nateglinide is a generic version of Novartis, Starlix(R). ... to IMS Health data. Par will begin shipping the 60mg ...
... , , WARSAW, Ind., ... leading independent provider of products to the global orthopedic device industry and ... Executive Officer, and Fred L. Hite, Senior Vice President and Chief Financial ... at the Grand Hyatt Grand Central Hotel in New York City on ...
... , , NEW DELHI, Sept. 10 ... in India -- today announced an inspiring list of speakers for the ... theme of TEDIndia is "The Future Beckons." , , ... from diverse disciplines. Doctor and researcher Hans Rosling will share ...
Cached Medicine News:Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 2Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 3Health News:Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 3Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 4Health News:Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R) 2Health News:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 3Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 4Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 5Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 6
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Medicine Products: